BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 36255032)

  • 21. Interventions to improve endocrine therapy adherence in breast cancer survivors: what is the evidence?
    Ekinci E; Nathoo S; Korattyil T; Vadhariya A; Zaghloul HA; Niravath PA; Abughosh SM; Trivedi MV
    J Cancer Surviv; 2018 Jun; 12(3):348-356. PubMed ID: 29396760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systematic adaptation of the adherence improving self-management strategy to support breast cancer survivors' adherence to adjuvant endocrine therapy: An intervention mapping approach.
    Janssen AM; Dam J; Prins J; Buffart LM; de Bruin M
    Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13721. PubMed ID: 36263723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Partner status moderates the relationships between sexual problems and self-efficacy for managing sexual problems and psychosocial quality-of-life for postmenopausal breast cancer survivors taking adjuvant endocrine therapy.
    Dorfman CS; Arthur SS; Kimmick GG; Westbrook KW; Marcom PK; Corbett C; Edmond SN; Shelby RA
    Menopause; 2019 Aug; 26(8):823-832. PubMed ID: 30994574
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The experiences of adjuvant endocrine therapy for women breast cancer survivors: A literature review.
    Long Y; Xie S; Liu Q; Xu F; Li Q; Wang N; Zhang Y
    Medicine (Baltimore); 2023 Dec; 102(51):e36704. PubMed ID: 38134074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence to oral endocrine therapy in racial/ethnic minority patients with low socioeconomic status before and during the COVID-19 pandemic.
    Rahimi S; Ononogbu O; Mohan A; Moussa D; Abughosh S; Trivedi MV
    Int J Clin Pharm; 2023 Dec; 45(6):1396-1404. PubMed ID: 37380914
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sociodemographic, clinical, psychosocial, and healthcare-related factors associated with beliefs about adjuvant endocrine therapy among breast cancer survivors.
    Sutton AL; Salgado TM; He J; Hurtado-de-Mendoza A; Sheppard VB
    Support Care Cancer; 2020 Sep; 28(9):4147-4154. PubMed ID: 31897782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modifiable risk factors for adherence to adjuvant endocrine therapy among breast cancer patients.
    Jacob Arriola KR; Mason TA; Bannon KA; Holmes C; Powell CL; Horne K; O'Regan R
    Patient Educ Couns; 2014 Apr; 95(1):98-103. PubMed ID: 24492157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deconstructing Decisions to Initiate, Maintain, or Discontinue Adjuvant Endocrine Therapy in Breast Cancer Survivors: A Mixed-Methods Study.
    Bluethmann SM; Murphy CC; Tiro JA; Mollica MA; Vernon SW; Bartholomew LK
    Oncol Nurs Forum; 2017 May; 44(3):E101-E110. PubMed ID: 28635973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review.
    Lambert LK; Balneaves LG; Howard AF; Gotay CC
    Breast Cancer Res Treat; 2018 Feb; 167(3):615-633. PubMed ID: 29110151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Applying the theory of planned behavior to examine adjuvant endocrine therapy adherence intentions.
    Hurtado-de-Mendoza A; Carrera P; Parrott WG; Gómez-Trillos S; Perera RA; Sheppard VB
    Psychooncology; 2019 Jan; 28(1):187-194. PubMed ID: 30353610
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence.
    Lee C; Check DK; Manace Brenman L; Kushi LH; Epstein MM; Neslund-Dudas C; Pawloski PA; Achacoso N; Laurent C; Fehrenbacher L; Habel LA
    Breast Cancer Res Treat; 2020 Feb; 180(1):219-226. PubMed ID: 31975315
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical factors associated with patterns of endocrine therapy adherence in premenopausal breast cancer patients.
    Woolpert KM; Schmidt JA; Ahern TP; Hjorth CF; Farkas DK; Ejlertsen B; Collin LJ; Lash TL; Cronin-Fenton DP
    Breast Cancer Res; 2024 Apr; 26(1):59. PubMed ID: 38589932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predicting adjuvant endocrine therapy initiation and adherence among older women with early-stage breast cancer.
    Meneveau MO; Keim-Malpass J; Camacho TF; Anderson RT; Showalter SL
    Breast Cancer Res Treat; 2020 Dec; 184(3):805-816. PubMed ID: 32920742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Association Between Out-of-Pocket Costs and Adherence to Adjuvant Endocrine Therapy Among Newly Diagnosed Breast Cancer Patients.
    Farias AJ; Hansen RN; Zeliadt SB; Ornelas IJ; Li CI; Thompson B
    Am J Clin Oncol; 2018 Jul; 41(7):708-715. PubMed ID: 27893470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interventions to promote adherence to endocrine therapy among breast cancer survivors: A meta-analysis.
    Finitsis DJ; Vose BA; Mahalak JG; Salner AL
    Psychooncology; 2019 Feb; 28(2):255-263. PubMed ID: 30511789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physical activity, health-related quality of life, and adjuvant endocrine therapy-related symptoms in women with hormone receptor-positive breast cancer.
    Sheppard VB; Dash C; Nomura S; Sutton AL; Franco RL; Lucas A; Ross M; Adams-Campbell L
    Cancer; 2020 Sep; 126(17):4059-4066. PubMed ID: 32614992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States.
    Daly B; Olopade OI; Hou N; Yao K; Winchester DJ; Huo D
    JAMA Oncol; 2017 Jul; 3(7):928-935. PubMed ID: 28152150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The lived experience of patients with breast cancer on adjuvant endocrine therapy: side effects and coping strategies during the first year of medication initiation.
    Gomaa S; Lopez A; Slamon R; Smith R; Lapitan E; Nightingale G; Miller SM; Wen KY
    Support Care Cancer; 2023 Nov; 31(12):719. PubMed ID: 38008817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer.
    Moy B; Tu D; Pater JL; Ingle JN; Shepherd LE; Whelan TJ; Goss PE
    Ann Oncol; 2006 Nov; 17(11):1637-43. PubMed ID: 16936184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding Breast Cancer Survivors' Beliefs and Concerns About Adjuvant Hormonal Therapy: Promoting Adherence.
    Hurtado-de-Mendoza A; Jensen RE; Jennings Y; Sheppard VB
    J Cancer Educ; 2018 Apr; 33(2):436-439. PubMed ID: 28205022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.